Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $550,000.00

Analysts expect VYNE Therapeutics Inc. (NASDAQ:VYNEGet Rating) to post sales of $550,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VYNE Therapeutics’ earnings, with estimates ranging from $300,000.00 to $800,000.00. VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that VYNE Therapeutics will report full-year sales of $4.20 million for the current year, with estimates ranging from $1.00 million to $10.00 million. For the next year, analysts expect that the business will post sales of $7.27 million, with estimates ranging from $800,000.00 to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNEGet Rating) last released its quarterly earnings results on Thursday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22). VYNE Therapeutics had a negative net margin of 496.98% and a negative return on equity of 106.54%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.09 million.

VYNE has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of VYNE Therapeutics in a research note on Friday, March 18th. Zacks Investment Research raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 13th.

VYNE Therapeutics stock opened at $0.45 on Friday. The company’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.88. VYNE Therapeutics has a 1 year low of $0.44 and a 1 year high of $5.47. The stock has a market capitalization of $25.21 million, a P/E ratio of -0.31 and a beta of 0.96.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. DSC Advisors L.P. boosted its stake in VYNE Therapeutics by 131.9% during the 4th quarter. DSC Advisors L.P. now owns 2,551,000 shares of the company’s stock worth $2,602,000 after purchasing an additional 1,451,000 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of VYNE Therapeutics by 1.1% during the 3rd quarter. Franklin Resources Inc. now owns 1,921,236 shares of the company’s stock valued at $2,671,000 after acquiring an additional 20,373 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of VYNE Therapeutics by 300.4% during the 3rd quarter. Renaissance Technologies LLC now owns 1,245,027 shares of the company’s stock valued at $1,731,000 after acquiring an additional 934,100 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of VYNE Therapeutics by 135.7% during the 4th quarter. GSA Capital Partners LLP now owns 217,747 shares of the company’s stock valued at $222,000 after acquiring an additional 125,345 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of VYNE Therapeutics by 438.6% during the 2nd quarter. Morgan Stanley now owns 203,075 shares of the company’s stock valued at $713,000 after acquiring an additional 165,372 shares during the last quarter. 26.73% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile (Get Rating)

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.

Recommended Stories

Get a free copy of the Zacks research report on VYNE Therapeutics (VYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VYNE Therapeutics (NASDAQ:VYNE)

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.